Estados Unidos · Plataformas y datos · MarketBeat

Rani Therapeutics Eyes 2027 Obesity Data as Oral Biologics Platform Advances

Publicado por MarketBeat · Estados Unidos hace 1 h

Rani Therapeutics (NASDAQ:RANI) outlined progress for its oral biologics delivery platform, including plans to advance its obesity program RT-114 and expectations for additional…

Leer el artículo completo en MarketBeat Inicie sesión para guardar

MarketNews muestra el titular y el resumen publicados por el medio. El artículo completo se lee en el sitio del editor. (www.marketbeat.com)

Rani Therapeutics Eyes 2027 Obesity Data as Oral Biologics Platform Advances

También te puede interesar

Forget the Anthropic IPO. Here Are 6 Stocks Worth Watching.

The Social Security Administration wants more babies signed up for ‘Trump accounts.’ But there’s still a catch.

Bank of Korea holds rates, upbeat outlook points to future hikes

FUN Stock Heads For 4th Week Of Loss: Analyst Sees 29% Downside Ahead Of Earnings As Mounting Debt, Weak Sales Loom

KFC rolls out 13 days of Halloween deals, but there’s a catch

Goldman Sachs, JPMorgan and Morgan Stanley are dominating the AI stock boom. Here's their edge

Rani Therapeutics Eyes 2027 Obesity Data as Oral Biologics Platform Advances

Compartir

También te puede interesar

Forget the Anthropic IPO. Here Are 6 Stocks Worth Watching.

The Social Security Administration wants more babies signed up for ‘Trump accounts.’ But there’s still a catch.

Bank of Korea holds rates, upbeat outlook points to future hikes

FUN Stock Heads For 4th Week Of Loss: Analyst Sees 29% Downside Ahead Of Earnings As Mounting Debt, Weak Sales Loom

KFC rolls out 13 days of Halloween deals, but there’s a catch

Goldman Sachs, JPMorgan and Morgan Stanley are dominating the AI stock boom. Here's their edge